Quantcast

Latest Mylan Inc. Stories

2014-03-11 16:26:16

Company launches anti-fungal AmBisome® as one of the segment's first product offerings MUMBAI, India and PITTSBURGH, March 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched a Critical Care segment in India. The new segment focuses on anti-fungal, antibiotics and anti-coagulant therapies. AmBisome(®), a leading...

2014-02-28 08:25:44

PITTSBURGH, Feb. 28, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the Company will present at the Barclays Global Healthcare Conference on Tuesday, March 11, 2014, in Miami. The presentation is scheduled to begin at 2:00 p.m. ET. Interested parties can access a live webcast of the presentation via the investor relations section of Mylan's Web site at http://mylan.com/investors. An...

2014-02-28 08:25:10

PITTSBURGH, Feb. 28, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the Company will present at the Cowen and Company 34(th) Annual Health Care Conference on Tuesday, March 4, 2014, in Boston. The presentation is scheduled to begin at 8:40 a.m. ET. Interested parties can access a live webcast of the presentation via the investor relations section of Mylan's Web site at...

2014-02-27 08:29:14

Provides 2014 Adjusted Diluted EPS Guidance Range of $3.25 - $3.60 and 2014 Revenue Guidance of $7.8 billion - $8.2 billion, Representing Year-Over-Year Growth of 19% and 16%, Respectively PITTSBURGH, Feb. 27, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three months and year ended December 31, 2013. Financial Highlights -- Adjusted diluted EPS of $0.78 for the three months ended December 31, 2013 compared to $0.65 for the same...

2014-02-14 12:24:15

PITTSBURGH, Feb. 14, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Agila Specialties Private Limited is conducting a voluntary nationwide recall to the hospital/user level of 10 lots of Etomidate Injection 2 mg/mL - 10 mL and 20 mL (see lot breakdown below). The 10 lots were manufactured by Agila Specialties Polska sp.zo.o in Warsaw, Poland. All of the products bear a Pfizer label. Agila Specialties Private Limited initiated the recall on Feb. 13, 2014,...

2014-02-11 12:26:51

PITTSBURGH, Feb. 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) announced today that it will host a conference call and live webcast, including a slide presentation, on Thursday, Feb. 27, 2014, at 10:00 a.m. ET, to review the company's financial results for the fourth quarter and year ended Dec. 31, 2013. The company also will be providing its financial guidance for 2014. Mylan will release its financial results on Feb. 27 before the market opens. The dial-in number to access the...

2014-02-03 00:21:09

Availability of 150 mg formulation increases dosing convenience and flexibility MUMBAI and PITTSBURGH, Feb. 3, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched the world's first trastuzumab biosimilar in India. The product, which will be marketed by Mylan under the brand name Hertraz(TM), is a biosimilar to Roche's...

2014-01-31 00:21:48

PITTSBURGH and MUMBAI, India, Jan. 31, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its India-based subsidiary Mylan Pharmaceuticals Private Limited has been named Gilead Sciences, Inc.'s (Nasdaq: GILD) exclusive branded medicines business partner for India. Under the agreement, Mylan will market and distribute in India Gilead's: -- HIV therapies Viread(® )(tenofovir disoproxil fumarate), Truvada(®) (emtricitabine/tenofovir disoproxil fumarate) and the...

2014-01-23 16:24:38

PITTSBURGH, Jan. 23, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Repaglinide Tablets, 0.5 mg, 1 mg and 2 mg. This product is the generic version of Novo Nordisk's Prandin(®), which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.(1) The company received final approval from the U.S. Food and Drug Administration (FDA) for its...

2014-01-09 08:27:16

PITTSBURGH, Jan. 9, 2014 /PRNewswire/ -- Mylan, Inc. (Nasdaq: MYL) today announced that Zyomyx's MyT4(TM) point-of-care CD4 diagnostic test has received the CE Certificate of Conformity in the European Union, an important step toward launching this innovative test and expanding access to affordable, accessible and reliable diagnostics for people living with HIV globally. As a result, the MyT4(TM) CD4 test can now bear the CE Mark, which demonstrates that the MyT4(TM) CD4 test complies...


Word of the Day
out-herod
  • In the phrase to out-herod Herod, to be more violent than Herod (as represented in the old mystery plays); hence, to exceed in any excess of evil.
Herod refers to 'Herod the Great,' a Roman client king and 'a madman who murdered his own family and a great many rabbis.' According to the OED, the term is 'chiefly with allusion to Shakespeare's use' in Hamlet.
Related